{"entity":{"id":"crinetics-pharmaceuticals","kind":"company","name":"Crinetics Pharmaceuticals","aka":["Crinetics Pharmaceuticals Inc."],"tldr":"Crinetics Pharmaceuticals is a United States-based biotechnology company running 3 late-stage cancer trials of CRN09682 in neuroendocrine tumours and pancreatic ductal adenocarcinoma.","summary":"Crinetics Pharmaceuticals, based in San Diego, the United States, is a biotechnology company and part of Vertex Pharmaceuticals. Crinetics Pharmaceuticals is an endocrinology-focused pharmaceutical company that develops therapies for endocrine diseases and endocrine-related tumours. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing CRN09682 in neuroendocrine tumours and pancreatic ductal adenocarcinoma. The largest, NCT07129252 (A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumours), plans to enrol 150 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Crinetics_Pharmaceuticals","links":[{"label":"Official website","url":"https://www.crinetics.com"},{"label":"ClinicalTrials.gov: trials led by Crinetics Pharmaceuticals","url":"https://clinicaltrials.gov/search?lead=Crinetics%20Pharmaceuticals%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["neuroendocrine","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07129252","nct05804669","nct07087054"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"San Diego","country":"US","companyType":"biotech","website":"https://www.crinetics.com","stage":"acquired","investors":[],"funding":[]},"route":"/companies/crinetics-pharmaceuticals/","neighbours":{"cancer":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"trial":[{"id":"nct05804669","kind":"trial","name":"A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome","route":"/trials/nct05804669/"},{"id":"nct07129252","kind":"trial","name":"A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors","route":"/trials/nct07129252/"},{"id":"nct07087054","kind":"trial","name":"Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen","route":"/trials/nct07087054/"}],"drug":[{"id":"paltusotine","kind":"drug","name":"Paltusotine","route":"/drugs/paltusotine/"}]}}